News


All series


All News

The FDA has approved the PD-1 inhibitor pembrolizumab as a second-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma for those who have progression on a platinum chemotherapy. 

A recent phase II trial examining nivolumab (Opdivo) in patients with anal cancer seeks to explore the biological makeup, and uncover potential biomarkers in anal cancer.

A study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy is hoping to reduce the risk of metastasis and death from prostate cancer for these high-risk patients, according to the study’s global principal investigator, Howard M. Sandler, MD.

Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response (pCR) rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P) versus trastuzumab emtansine (T-DM1) plus pertuzumab (T-DM1+P).  

The FDA has agreed to review nivolumab under an accelerated timeframe for its potential as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.